Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Rhythm Pharmaceuticals stock | 21.89

Own Rhythm Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Rhythm Pharmaceuticals, Inc is a biotechnology business based in the US. Rhythm Pharmaceuticals shares (RYTM) are listed on the NASDAQ and all prices are listed in US Dollars. Rhythm Pharmaceuticals employs 70 staff and has a market cap (total outstanding shares value) of USD$969.4 million.

How to buy shares in Rhythm Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Rhythm Pharmaceuticals. Find the stock by name or ticker symbol: RYTM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Rhythm Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$21.89, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Rhythm Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Rhythm Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Rhythm Pharmaceuticals share price

Use our graph to track the performance of RYTM stocks over time.

Rhythm Pharmaceuticals shares at a glance

Information last updated 2020-11-23.
Latest market close USD$21.89
52-week range USD$12.99 - USD$32.24
50-day moving average USD$23.0631
200-day moving average USD$22.3393
Wall St. target price USD$34.13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.341

Buy Rhythm Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Rhythm Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rhythm Pharmaceuticals price performance over time

Historical closes compared with the close of $21.89 from 2020-11-16

1 week (2020-11-19) N/A
1 month (2020-10-26) N/A
3 months (2020-08-26) N/A
6 months (2020-05-26) N/A
1 year (2019-11-26) N/A
2 years (2018-11-26) N/A
3 years (2017-11-26) N/A
5 years (2015-11-26) N/A

Rhythm Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -43.17%
Return on equity TTM -76.32%
Profit margin 0%
Book value $4.455
Market capitalisation USD$969.4 million

TTM: trailing 12 months

Shorting Rhythm Pharmaceuticals shares

There are currently 1.8 million Rhythm Pharmaceuticals shares held short by investors – that's known as Rhythm Pharmaceuticals's "short interest". This figure is 12.1% down from 2.0 million last month.

There are a few different ways that this level of interest in shorting Rhythm Pharmaceuticals shares can be evaluated.

Rhythm Pharmaceuticals's "short interest ratio" (SIR)

Rhythm Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rhythm Pharmaceuticals shares currently shorted divided by the average quantity of Rhythm Pharmaceuticals shares traded daily (recently around 218776.62178703). Rhythm Pharmaceuticals's SIR currently stands at 8.17. In other words for every 100,000 Rhythm Pharmaceuticals shares traded daily on the market, roughly 8170 shares are currently held short.

However Rhythm Pharmaceuticals's short interest can also be evaluated against the total number of Rhythm Pharmaceuticals shares, or, against the total number of tradable Rhythm Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rhythm Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Rhythm Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.058% of the tradable shares (for every 100,000 tradable Rhythm Pharmaceuticals shares, roughly 58 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Rhythm Pharmaceuticals.

Find out more about how you can short Rhythm Pharmaceuticals stock.

Rhythm Pharmaceuticals share dividends

We're not expecting Rhythm Pharmaceuticals to pay a dividend over the next 12 months.

Rhythm Pharmaceuticals share price volatility

Over the last 12 months, Rhythm Pharmaceuticals's shares have ranged in value from as little as $12.99 up to $32.24. A popular way to gauge a stock's volatility is its "beta".

RYTM.US volatility(beta: 1.28)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rhythm Pharmaceuticals's is 1.2796. This would suggest that Rhythm Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Rhythm Pharmaceuticals overview

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site